What are the indications, dosing regimens, and contraindications for phentolamine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Phentolamine: Indications, Dosing, and Contraindications

Phentolamine is a nonselective α-adrenergic blocker indicated primarily for pheochromocytoma-related hypertensive crises, prevention/treatment of norepinephrine extravasation, and sympathomimetic toxicity—not for routine hypertensive emergencies. 1


Primary Indications

1. Pheochromocytoma Management

  • Preoperative blood pressure control: Administer 5 mg IV or IM (1 mg in children) 1–2 hours before surgery, repeated as necessary to prevent hypertensive paroxysms. 1
  • Intraoperative hypertensive crises: Give 5 mg IV (1 mg in children) during surgery to control acute blood pressure spikes, tachycardia, or catecholamine-induced complications. 1
  • Diagnostic testing (phentolamine blocking test): Inject 5 mg IV (1 mg in children) after stabilizing baseline blood pressure; a positive response (systolic drop >35 mmHg, diastolic >25 mmHg within 2 minutes) suggests pheochromocytoma but requires confirmation with urinary catecholamine measurements. 1

2. Norepinephrine Extravasation

  • Prevention: Add 10 mg phentolamine to each liter of norepinephrine infusion without affecting pressor activity. 1
  • Treatment: Inject 5–10 mg phentolamine in 10 mL saline into the extravasation site within 12 hours to prevent dermal necrosis and tissue sloughing. 1

3. Sympathomimetic Toxicity (Amphetamine/Cocaine/MDMA)

  • After benzodiazepine failure: The European Society of Cardiology recommends phentolamine for refractory hypertension in amphetamine/MDMA intoxication only after adequate sedation with benzodiazepines, which remain first-line therapy. 2, 3
  • Dosing in toxicity: Use 5–10 mg IV titrated to effect, targeting a 20–25% reduction in mean arterial pressure within the first hour, then gradual reduction to <160/100 mmHg over 2–6 hours. 2
  • Critical contraindication: Never use β-blockers (including labetalol) in sympathomimetic toxicity, as unopposed α-stimulation causes paradoxical hypertension; phentolamine provides selective α-blockade. 2, 3

Absolute Contraindications

  • Myocardial infarction (current or history). 1
  • Coronary insufficiency or angina. 1
  • Any evidence of coronary artery disease. 1
  • Hypersensitivity to phentolamine or related compounds. 1

Dosing Regimens by Indication

Indication Adult Dose Pediatric Dose Route Timing
Pheochromocytoma (preop) 5 mg 1 mg IV or IM 1–2 h before surgery [1]
Pheochromocytoma (intraop) 5 mg 1 mg IV As needed during surgery [1]
Norepinephrine extravasation 5–10 mg in 10 mL saline Same Local infiltration Within 12 h of extravasation [1]
Sympathomimetic toxicity 5–10 mg titrated Not specified IV After benzodiazepines [2]
Diagnostic test 5 mg 1 mg IV (rapid) After 30 min BP stabilization [1]

Critical Clinical Considerations

When Phentolamine Is NOT Appropriate

  • Routine hypertensive emergencies: Nicardipine, labetalol, or clevidipine are preferred first-line agents for most hypertensive emergencies; phentolamine is reserved for catecholamine-excess states. 4
  • Hypertensive urgency (no organ damage): Oral agents (captopril, extended-release nifedipine, labetalol) are indicated—never IV phentolamine. 4
  • Acute coronary syndrome: Nitroglycerin is first-line; phentolamine is contraindicated due to coronary disease exclusion. 4, 1

Sympathomimetic Toxicity Algorithm

  1. First-line: Benzodiazepines (diazepam) to reduce catecholamine surge and control hypertension/tachycardia. 2, 3
  2. Second-line (if BP remains >180/120 mmHg): Phentolamine or nicardipine IV. 2
  3. Avoid: β-blockers as monotherapy (risk of unopposed α-stimulation). 2, 3
  4. Adjunct for coronary ischemia: Add nitroglycerin and aspirin. 2

Monitoring Requirements

  • Diagnostic test: Record blood pressure every 30 seconds for 3 minutes, then every 60 seconds for 7 minutes after injection; maximal effect occurs within 2 minutes. 1
  • Therapeutic use: Continuous cardiovascular monitoring in ICU settings for pheochromocytoma or sympathomimetic toxicity. 2
  • Hypotension management: If dangerous blood pressure drops occur, treat with norepinephrine (postoperatively after pheochromocytoma removal). 1

Common Pitfalls

  • Misusing phentolamine for routine hypertensive emergencies: This drug is not a first-line agent for most hypertensive crises; nicardipine or labetalol are preferred unless catecholamine excess is confirmed. 4, 2
  • Administering before benzodiazepines in sympathomimetic toxicity: Benzodiazepines must be optimized first to address the underlying catecholamine surge. 2, 3
  • Ignoring coronary contraindications: Phentolamine is absolutely contraindicated in any patient with coronary artery disease, angina, or MI history. 1
  • Delaying extravasation treatment: Phentolamine must be infiltrated within 12 hours of norepinephrine extravasation to prevent tissue necrosis. 1
  • Over-reliance on diagnostic testing: A negative phentolamine test does not exclude pheochromocytoma, especially in paroxysmal hypertension; urinary catecholamine measurements are required for confirmation. 1

Alternative Uses (Non-Hypertensive)

  • Reversal of local anesthesia: Phentolamine 0.4 mg (OraVerse) reduces median lip recovery time by 75–85 minutes after dental procedures, with mild conjunctival hyperemia as the primary adverse effect. 5, 6
  • Reversal of pharmacologic mydriasis: 0.75% phentolamine ophthalmic solution reverses pupil dilation within 60–90 minutes, reducing time to baseline by 5–6 hours compared to placebo. 7
  • Erectile dysfunction: Oral phentolamine 40–80 mg has shown modest efficacy in mild-to-moderate ED, though not FDA-approved for this indication. 8, 9

References

Guideline

Management of Severe Hypertension and Tachycardia in Amphetamine/MDMA Intoxication

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Sympathomimetic Toxidrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment for New Hypertension in the Emergency Room

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Efficacy of phentolamine mesylate in reducing the duration of various local anesthetics.

Journal of dental anesthesia and pain medicine, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.